Novartis Lp(a) Drug Flop Shakes Amgen and Lilly Race
Novartis struck out in the cholesterol drug race, raising the pressure on Amgen and Eli Lilly to prove their Lp(a) candidates actually work.
Novartis just handed the market a wake-up call. Its experimental Lp(a)-lowering drug failed to deliver, and now every investor holding Amgen or Eli Lilly stock has a reason to sweat. This isn't a minor pipeline hiccup — it's a shot across the bow of a multibillion-dollar race that Wall Street has been watching closely.
Lp(a), short for lipoprotein(a), is a cholesterol-like particle linked to heart attacks and strokes. The core scientific bet is simple: drive Lp(a) levels down, and you protect patients from cardiovascular events. Novartis was supposed to help validate that thesis. Instead, its stumble raises an uncomfortable question — does lowering Lp(a) actually translate into fewer heart attacks, or has the whole field been chasing a biomarker that doesn't move the needle clinically?
Read more Apple's Foldable iPhone Duo Arrives — Don't Expect a Stock Surge →
That question lands hardest on Amgen and Eli Lilly, who are still deep in the race with their own Lp(a)-targeting programs. Both companies have significant capital and credibility on the line. A Novartis failure doesn't automatically doom their drugs, but it absolutely resets expectations. Investors and analysts will now demand a much higher bar of proof before pricing in blockbuster revenue.
For traders, the calculus is straightforward: this is a risk-off moment for the Lp(a) space. Watch for volatility in Amgen and Lilly shares as the market reprices the probability that their candidates will clear the clinical and regulatory hurdles ahead. The upside is still massive if either company succeeds — but the Novartis setback just made the path there look a lot narrower.
Continue reading at US Top News and Analysis.
